Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.
Identifieur interne : 000D37 ( Main/Exploration ); précédent : 000D36; suivant : 000D38Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.
Auteurs : Mariana Babayeva [États-Unis] ; Zvi Loewy [États-Unis]Source :
- Pharmacogenomics and personalized medicine [ 1178-7066 ] ; 2020.
Abstract
Background
A new coronavirus SARS-CoV-2 has been identified as the etiological agent of the severe acute respiratory syndrome, COVID-19, the source and cause of the 2019-20 coronavirus pandemic. Hydroxychloroquine and chloroquine have gathered extraordinary attention as therapeutic candidates against SARS-CoV-2 infections. While there is growing scientific data on the therapeutic effect, there is also concern for toxicity of the medications. The therapy of COVID-19 by hydroxychloroquine and chloroquine is off-label. Studies to analyze the personalized effect and safety are lacking.
Methods
A review of the literature was performed using Medline/PubMed/Embase database. A variety of keywords were employed in keyword/title/abstract searches. The electronic search was followed by extensive hand searching using reference lists from the identified articles.
Results
A total of 126 results were obtained after screening all sources. Mechanisms underlying variability in drug concentrations and therapeutic response with chloroquine and hydroxychloroquine in mediating beneficial and adverse effects of chloroquine and hydroxychloroquine were reviewed and analyzed. Pharmacogenomic studies from various disease states were evaluated to elucidate the role of genetic variation in drug response and toxicity.
Conclusion
Knowledge of the pharmacokinetics and pharmacogenomics of chloroquine and hydroxychloroquine is necessary for effective and safe dosing and to avoid treatment failure and severe complications.
DOI: 10.2147/PGPM.S275964
PubMed: 33122936
PubMed Central: PMC7591012
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.</title>
<author><name sortKey="Babayeva, Mariana" sort="Babayeva, Mariana" uniqKey="Babayeva M" first="Mariana" last="Babayeva">Mariana Babayeva</name>
<affiliation wicri:level="2"><nlm:affiliation>Touro College of Pharmacy, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Touro College of Pharmacy, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Loewy, Zvi" sort="Loewy, Zvi" uniqKey="Loewy Z" first="Zvi" last="Loewy">Zvi Loewy</name>
<affiliation wicri:level="2"><nlm:affiliation>Touro College of Pharmacy, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Touro College of Pharmacy, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>New York Medical College, Valhalla, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Medical College, Valhalla, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33122936</idno>
<idno type="pmid">33122936</idno>
<idno type="doi">10.2147/PGPM.S275964</idno>
<idno type="pmc">PMC7591012</idno>
<idno type="wicri:Area/Main/Corpus">000926</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000926</idno>
<idno type="wicri:Area/Main/Curation">000926</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000926</idno>
<idno type="wicri:Area/Main/Exploration">000926</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.</title>
<author><name sortKey="Babayeva, Mariana" sort="Babayeva, Mariana" uniqKey="Babayeva M" first="Mariana" last="Babayeva">Mariana Babayeva</name>
<affiliation wicri:level="2"><nlm:affiliation>Touro College of Pharmacy, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Touro College of Pharmacy, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Loewy, Zvi" sort="Loewy, Zvi" uniqKey="Loewy Z" first="Zvi" last="Loewy">Zvi Loewy</name>
<affiliation wicri:level="2"><nlm:affiliation>Touro College of Pharmacy, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Touro College of Pharmacy, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>New York Medical College, Valhalla, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>New York Medical College, Valhalla, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Pharmacogenomics and personalized medicine</title>
<idno type="ISSN">1178-7066</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>Background</b>
</p>
<p>A new coronavirus SARS-CoV-2 has been identified as the etiological agent of the severe acute respiratory syndrome, COVID-19, the source and cause of the 2019-20 coronavirus pandemic. Hydroxychloroquine and chloroquine have gathered extraordinary attention as therapeutic candidates against SARS-CoV-2 infections. While there is growing scientific data on the therapeutic effect, there is also concern for toxicity of the medications. The therapy of COVID-19 by hydroxychloroquine and chloroquine is off-label. Studies to analyze the personalized effect and safety are lacking.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Methods</b>
</p>
<p>A review of the literature was performed using Medline/PubMed/Embase database. A variety of keywords were employed in keyword/title/abstract searches. The electronic search was followed by extensive hand searching using reference lists from the identified articles.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Results</b>
</p>
<p>A total of 126 results were obtained after screening all sources. Mechanisms underlying variability in drug concentrations and therapeutic response with chloroquine and hydroxychloroquine in mediating beneficial and adverse effects of chloroquine and hydroxychloroquine were reviewed and analyzed. Pharmacogenomic studies from various disease states were evaluated to elucidate the role of genetic variation in drug response and toxicity.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>Conclusion</b>
</p>
<p>Knowledge of the pharmacokinetics and pharmacogenomics of chloroquine and hydroxychloroquine is necessary for effective and safe dosing and to avoid treatment failure and severe complications.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33122936</PMID>
<DateRevised><Year>2020</Year>
<Month>10</Month>
<Day>31</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1178-7066</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Pharmacogenomics and personalized medicine</Title>
<ISOAbbreviation>Pharmgenomics Pers Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.</ArticleTitle>
<Pagination><MedlinePgn>531-542</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2147/PGPM.S275964</ELocationID>
<Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">A new coronavirus SARS-CoV-2 has been identified as the etiological agent of the severe acute respiratory syndrome, COVID-19, the source and cause of the 2019-20 coronavirus pandemic. Hydroxychloroquine and chloroquine have gathered extraordinary attention as therapeutic candidates against SARS-CoV-2 infections. While there is growing scientific data on the therapeutic effect, there is also concern for toxicity of the medications. The therapy of COVID-19 by hydroxychloroquine and chloroquine is off-label. Studies to analyze the personalized effect and safety are lacking.</AbstractText>
<AbstractText Label="Methods" NlmCategory="UNASSIGNED">A review of the literature was performed using Medline/PubMed/Embase database. A variety of keywords were employed in keyword/title/abstract searches. The electronic search was followed by extensive hand searching using reference lists from the identified articles.</AbstractText>
<AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 126 results were obtained after screening all sources. Mechanisms underlying variability in drug concentrations and therapeutic response with chloroquine and hydroxychloroquine in mediating beneficial and adverse effects of chloroquine and hydroxychloroquine were reviewed and analyzed. Pharmacogenomic studies from various disease states were evaluated to elucidate the role of genetic variation in drug response and toxicity.</AbstractText>
<AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Knowledge of the pharmacokinetics and pharmacogenomics of chloroquine and hydroxychloroquine is necessary for effective and safe dosing and to avoid treatment failure and severe complications.</AbstractText>
<CopyrightInformation>© 2020 Babayeva and Loewy.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Babayeva</LastName>
<ForeName>Mariana</ForeName>
<Initials>M</Initials>
<Identifier Source="ORCID">0000-0001-5758-5589</Identifier>
<AffiliationInfo><Affiliation>Touro College of Pharmacy, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Loewy</LastName>
<ForeName>Zvi</ForeName>
<Initials>Z</Initials>
<Identifier Source="ORCID">0000-0002-5008-2417</Identifier>
<AffiliationInfo><Affiliation>Touro College of Pharmacy, New York, NY, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>New York Medical College, Valhalla, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>10</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Pharmgenomics Pers Med</MedlineTA>
<NlmUniqueID>101514107</NlmUniqueID>
<ISSNLinking>1178-7066</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">chloroquine</Keyword>
<Keyword MajorTopicYN="N">hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">pharmacogenomics</Keyword>
<Keyword MajorTopicYN="N">pharmacokinetics</Keyword>
</KeywordList>
<CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>08</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>10</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>10</Month>
<Day>30</Day>
<Hour>5</Hour>
<Minute>52</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>10</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33122936</ArticleId>
<ArticleId IdType="doi">10.2147/PGPM.S275964</ArticleId>
<ArticleId IdType="pii">275964</ArticleId>
<ArticleId IdType="pmc">PMC7591012</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2005 Apr 14;352(15):1565-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15829537</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 2013 Dec;76(6):858-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23701202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):74-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8278822</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anesth Analg. 2008 Sep;107(3):926-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18713907</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 Apr;93:268-276</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32081774</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med (N Y). 2020 Jun 5;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Electrophoresis. 2006 Mar;27(5-6):1248-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16440402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2010 Apr 13;17(4):348-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20385360</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12406645</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 1983 Jul 18;75(1A):5-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6603166</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1993 Jul;36(1):78-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8373715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1995 Aug;40(2):127-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8562294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biochem Mol Toxicol. 1999;13(6):289-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10487415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Med. 2006;57:119-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16409140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 1987;65(1):47-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3495365</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Natl Cancer Inst. 1998 Aug 19;90(16):1225-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9719084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacogenomics J. 2009 Apr;9(2):127-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19172157</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 1996 Oct;31(4):257-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8896943</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Emerg Med. 2001 Sep;19(5):420-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11555803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hum Genet. 2009 Jan;54(1):40-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19158817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatol Rehabil. 1976 Aug;15(3):235-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">968356</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 1997;6(2):96-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9061657</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Case Rep Cardiol. 2016;2016:4626279</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27478650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2002 Jun;46(6):1460-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12115175</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21518836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 1983 Jul 18;75(1A):11-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6408923</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 1947 Nov;26(6):1168-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16695518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):82-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8278823</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochim Biophys Acta. 2014 Jun;1840(6):2032-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24556123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2016 Jun 14;534(7607):314-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27306171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1983 Mar;15(3):375-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6849768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Genet. 2014 Jul 02;15:76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24986243</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Toxicol Rep. 2014 Nov 04;1:963-968</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28962308</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1983 Apr;15(4):471-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6849784</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Metab Rev. 2002 Feb-May;34(1-2):83-448</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11996015</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 2000 Jun;49(6):549-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10848718</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Rheumatol. 2013 Aug;19(5):286-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23872551</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dermatol Ther. 2007 Jul-Aug;20(4):160-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17970883</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dermatol Ther. 2020 May;33(3):e13380</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32253799</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Pharmacol. 2004 Dec;60(10):709-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15619134</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arzneimittelforschung. 1992 Jun;42(6):825-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1418039</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Metab Dispos. 2003 Jun;31(6):748-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12756207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2012 Mar 01;11(3):191-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22378269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Inflammopharmacology. 2015 Oct;23(5):231-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26246395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 1994 Jun;37(6):830-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8003056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Pharmacol. 1987 Oct;27(10):813-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3323258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chirality. 1994;6(4):355-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8068493</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2011 Aug 09;7(9):537-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21826093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chirality. 1994;6(4):337-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8068491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Pharm Res. 2003 Aug;26(8):631-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12967198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacogenomics. 2016 Nov;17(17):1903-1911</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27767381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Sci. 2019 Jan;108(1):661-673</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30399360</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioimpacts. 2017;7(1):25-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28546950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19188392</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2016 Apr 05;11(4):e0152677</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27045516</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1986 Sep;22(3):356-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3768249</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Best Pract Res Clin Rheumatol. 2004 Apr;18(2):233-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15121042</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ophthalmology. 2011 Feb;118(2):415-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21292109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2011 Oct;90(4):625-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21900891</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Malar J. 2016 May 20;15(1):284</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27206924</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trans Am Ophthalmol Soc. 2007;105:191-4; discussion 195-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18427609</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):901-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10548319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Drug Discov. 2020 Apr;15(4):397-401</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31847616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Sci. 2016 Feb;105(2):884-890</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26429523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1987 Mar;23(3):295-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3567044</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Drug Investig. 2018 Aug;38(8):653-671</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29737455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 1993 Nov;20(11):1874-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8308772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1989 Jun;27(6):771-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2757893</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Drug Monit. 1989;11(4):369-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2662478</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1999 Oct 15;286(5439):487-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10521338</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Metab Dispos. 2001 Mar;29(3):268-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11181494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nephron. 1993;65(2):333</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8247209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EBioMedicine. 2017 Oct;24:189-194</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29033372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1996 Mar;41(3):244-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8866926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Invest Dermatol. 2011 Oct;131(10):1981-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21734714</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 2018 Jun;365(3):447-459</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29438998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunopharmacol Immunotoxicol. 2013 Jun;35(3):434-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23635029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheumatol. 2016 Jan;68(1):184-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26316040</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2020 Jun;57:279-283</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioanalysis. 2019 Mar;11(5):333-347</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30873854</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 1993 Nov;25(5):392-407</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7904547</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Baillieres Clin Rheumatol. 1990 Dec;4(3):467-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2093438</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 1967 Nov;158(2):323-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6065153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2017 Nov 17;7(1):15771</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29150641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Clin Trials. 2007 Jan 05;2(1):e6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17213921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17923-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16330770</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm Biomed Anal. 2005 Apr 1;37(4):703-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15797791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nephron. 1992;62(1):108-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1436274</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Pharmacol. 2004 Jan;59(11):803-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14652703</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 1999 Feb;42(2):357-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10025931</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Res Clin Pract. 2015 Jul;109(1):57-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26004431</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2017 Oct;102(4):688-700</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28378927</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genomics. 1995 Jul 20;28(2):328-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8530044</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Genet. 2004 Sep;5(9):669-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15372089</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacogenet Genomics. 2010 Jan;20(1):38-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19898263</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 1996 Jun;5 Suppl 1:S11-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8803904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 May 4;49(9):2845-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16640347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 2017 Mar;44(3):398</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28250164</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Babayeva, Mariana" sort="Babayeva, Mariana" uniqKey="Babayeva M" first="Mariana" last="Babayeva">Mariana Babayeva</name>
</region>
<name sortKey="Loewy, Zvi" sort="Loewy, Zvi" uniqKey="Loewy Z" first="Zvi" last="Loewy">Zvi Loewy</name>
<name sortKey="Loewy, Zvi" sort="Loewy, Zvi" uniqKey="Loewy Z" first="Zvi" last="Loewy">Zvi Loewy</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:33122936 |texte= Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33122936" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |